Portal de Periódicos da CAPES

Certolizumab pegol for the treatment of rheumatoid arthritis

2011; Taylor & Francis; Volume: 12; Issue: 2 Linguagem: Inglês

10.1517/14712598.2012.645533

1744-7682

Sarah Horton, Ceara AE Walsh, Paul Emery,

Chronic Lymphocytic Leukemia Research

Introduction: Improved understanding of the pathogenesis of rheumatoid arthritis (RA), and subsequent development of targeted therapies, have greatly advanced the management of this chronic inflammatory disease. The aim of treatment is a state of clinical remission. Certolizumab pegol (CZP) is a novel pegylated TNF alpha inhibitor (TNFi) therapy and is the focus of this review.